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ABSTRACT: Development of a straightforward strategy for simultaneous quantitative analysis of nonesterified 
fatty acids (NEFA) species in biofluids is a challenging task because of the extreme complexity of fatty acid distri -
bution in biological matrices. In this study, we present a direct immersion solid phase microextraction method 
coupled to liquid chromatography-mass spectrometry platform (DI-SPME- HPLC-ESI -MS ) for determination of 
unconjugated fatty acids (FA) in fish and human plasma. The proposed method was fully validated according to  
bioanalytical method validation guidelines. The LOD and LOQ were in the range of 0.5-2 and 5-12 ng/ml, respec -
tively, with a linear dynamic range of 100 fold for each compound. Absolute and relative matrix effects were  
comprehensively evaluated and found to be in the acceptable range of 91-116%. The affinity constant ( Ka) of in-
dividual FAs to protein albumin was determined to be 9.2×104 to 4.3×105 M－1. The plasma protein binding (PPB
%) was calculated, and found to be in the range of 98.0-99.7% for different polyunsaturated fatty acids (PUFAs).  
The PUFAs under study were found at a high concentration range in fish plasma, whereas only a few were within  
quantification  range  in  control  human  plasma. The  method  was  successfully  applied  for  monitoring  PUFA 
changes during the operation in plasma samples obtained from patients undergoing cardiac surgery with the use  
of cardiopulmonary bypass (CPB). The most significant contribution induced by surgery was noticed in the con -
centration level of α-linolenic acid (18:3, ALA), arachidonic acid (20:4, AA), and docosahexanoic acid (22:6, DHA)  
soon after administration of CPB in all cases. 
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Fatty acids (FA) are essential components of liv-
ing  cells  and  important  substrates  that  play  a 
critical  role  in  mammalian  energy  metabolism. 
Fatty acids are combined as the building blocks 
of more complex lipids through ester or  amide 
bonds.  These  lipids  will  form  the  lipid  bilayer 
membrane compositions, lipoporoteins and lipo-
somes.  Esterified fatty acids act  as suppliers of 
chemically stored energy, building blocks of cel-
lular membranes by esterification into phospho-
lipids  and  involving  in  signal  transducers  path-
ways.1 They  are  continuously  produced,  inte-
grated into lipids, and degraded in the  β-oxida-
tion pathway and citric acid cycle.2 On the other 
hand, fatty acids also exist in free form, (nones-
terified fatty acids; NEFA) in the biological media. 
Alterations in the metabolism of this portion is of 
specific interest since it is established to be asso-
ciated with pathological conditions and observed 
with  numerous  disorders,  such  as  obesity,3 in-
sulin resistance,4 diabetes mellitus,5 or metabolic 
syndrome.6 
Accurate determination of the composition of 
free fatty acids (FFA) in different biological matri-
ces is a predominant problem in total fat extrac-
tion.  The  most  common  procedures  used  to 
measure FFA concentration consist  of  multiple-
step methods, including (a) an extraction proce-
dure to isolate lipids from the sample bulk,  (b) 
separation of FFA from the rest of the lipids using 
conventional  methods  such  as  thin-layer  chro-
matography (TLC) and/or solid phase extraction 
(SPE),7,8 (c)  derivatization  of  FFA  to  fatty  acid 
methyl  esters  (FAMEs),9,10 and  (d)  a  final  chro-
matographic  method for  differentiation of  indi-
vidual fatty acid species.11 The chromatographic 
determination of FAMEs is by far mostly done us-
ing  capillary  gas  chromatography  (GC,)12–14 and 
less frequently by high performance liquid chro-
matography (HPLC).9,15,16 
Lipid  analysis  deals  with  enormous  sample 
complexity.  In  order  to  obtain  satisfactory  re-
sults, the extraction of lipids from complex bio-
logical matrices, which aims at removal and iso-
lation from interfering agents such as proteins, 
saccharides, or other small molecules, is usually 
indispensable  before  the  analysis.  Therefore,  a 
broad  range  of  extraction  techniques  are  cur-
rently used for this purpose.17 However, the most 
common  extraction  approaches  have  been 
mainly  based on solvent  extraction so  far.  The 
most  popular  extraction  methods  for  lipids  in-
clude the traditional Folch method,18 or a modi-
fied Folch method  13 that employs a solution of 
chloroform/methanol  (2:1,  v/v),  or  the  com-
monly called Bligh and Dyer method, in which a 
chloroform/ methanol/water mixture is used to 
extract the lipids.19 Moreover, exhaustive Soxhlet 
extraction is probably the most commonly used 
technique for the extraction of fats and oils from 
food  matrices.20 More  modern  methodologies 
take  advantage  of  solid-phase  extraction  (SPE) 
for fatty acid extraction,21 typically using amino-
bonded phase and C18 bonded-phase columns.22
In  comparison  to  liquid-liquid  extraction  (LLE) 
methods, these procedures are quite fast, mini-
mizing volumes of organic solvents and leading 
to  good  recovery  and  higher  reproducibility. 
However,  most  of  the  proposed  SPE  protocols 
offer  the  application  of  derivatization  or  liquid 
extraction followed by solvent  evaporation and 
reconstitution procedure.23 In addition, the  limi-
tations may include clogging of cartridges when 
handling complex matrixes such as plasma or tis-
sue. Considering  the exhaustive  nature  of  SPE, 
when dealing with a large volume of samples the 
recovery will be significantly reduced due to limi-
tations with breakthrough volume and the low 
peak capacity of SPE cartridges. 24–26
In  contrast,  among  all  extraction  techniques, 
solid  phase microextraction (SPME) is  sampling 
and sample preparation technique characterized 
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by simplicity, reproducibility and non-exhaustive 
nature of the extraction process when very small 
sorbent volume is used. The benefits of SPME for 
highly complex matrices such as biological sam-
ples have been already discussed elswhere.27–32
Headspace SPME (HS-SPME) has been previously 
reported  for  determination  of  short  chain 
volatile  fatty  acids,  including  the  C2-C7 carbon 
chain or their ethyl esters from waste water.33,34
However, extraction of long chain fatty acids in 
biological  and nutrition analysis  is  a  very  chal-
lenging  goal  due  to  their  hydrophobicity,  per-
ceived abundance as plasticizers, ubiquity in the 
environment, great tendency to bioconcentrate, 
vast distribution in conjugated forms in cellular 
structure, very high affinity to biological proteins 
such as albumin, and a high risk of matrix effect 
encounters. The main goal of this study is to ad-
dress the above mentioned challenges for unbi-
ased  high  throughput  quantification  of  “total” 
and  "free”  concentration  of  nonesterified  fatty 
acids  in the complex biological  media via  opti-
mization and validation of a SPME assay followed 
by  HPLC-ESI-MS. The method involves a simple 
SPME protocol with no necessity of using halo-
genated solvents  or  chemical  derivatization ap-
proaches that use highly reactive reagents. In the 
proposed method, entire procedure is simplified 
to immersion of  SPME fiber into the biological 
fluids  which  allows  for  extraction  of  the  NEFA 
without  interrupting  the  lipoproteins  or  cell 
membrane lipids. This is in contrast to the com-
monly  used  liquid  based  methods  which  only 
provide estimation of total concentration of fatty 
acids  due  to  the  disruption  of  protein-bound 
fractions  and  complex  lipid  structures  such  as 
lipoproteins  by  organic  solvents.  Therefore,  as 
the SPME extraction is non-exhaustive, the natu-
ral balance in the investigated system is not dis-
turbed and the obtained results provide informa-
tion about the actual equilibrium in the sample. 
 The possibility of encountering matrix effect in 
HPLC-ESI-MS analysis of human and fish plasma 
was evaluated using different  experimental  ap-
proaches.  The proposed method was fully  vali-
dated according to the bioanalytical method vali-
dation guidelines. The final protocol was applied 
to  monitor  PUFA  changes  in  plasma  obtained 
from a group of patients during cardiac surgery 
with  the  use  of  cardiopulmonary  bypass  (CPB) 
and to quantify level of the PUFAs in fish plasma. 
 EXPERIMENTAL SECTION
Plasma  samples Plasma  samples  were  ob-
tained  from  seven  patients  during  cardiac 
surgery involving the use of cardiopulmonary by-
pass (CPB). Blood samples were taken on a sam-
pling schedule order at 5, 10 and 15 minutes be-
fore  initiation  of  the  infusion;  5  minutes  after 
chest opening and 5 minutes before commenc-
ing CPB, following by frequent sampling every 30 
minutes during CPB; and 5, 60 and 120 minutes 
after  chest  closure.35–38 Perioperative  care  has 
been provided to  all  the  patients  as  described 
previously.  39 The  study approval  was  obtained 
from Toronto General Hospital/University Health 
Network  and  University  of  Waterloo  Research 
Ethics Boards. All the patients signed the consent 
to participate in the study.
Fish plasma samples were also collected from 
White Sucker (Catostomus commersoni) at Lake 
Superior (Provincial Park, ON) due to their wide-
spread availability in the watershed. Blood was 
collected  by  caudal  puncture  with  a  heparin-
coated needle and syringe (5cc) and centrifuged 
at 10000 rpm for 4 min to separate plasma. All 
plasma  samples  was  transferred  to  a  cryovial, 
snap-frozen in liquid nitrogen and stored at -80C 
until  analysis.  Animal  care  and all  investigative 
procedures adhered to the guidelines of the Of-
fice  of  Research  Ethics,  University  of  Waterloo 
(AUPP:10-17) and the Canadian Council  of  Ani-
mal Care. 
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Optimization of SPME Procedure C18 and mix-
mode fibers (Supelco, Bellefonte PA) were com-
pared during the preliminary stage of extraction 
phase  selection.  In  order  to  determine the ex-
traction  efficiency  and  reproducibility  of  the 
SPME  coatings,  a  phosphate  buffered  saline 
(PBS) at ph 7.4 was spiked with authentic stan-
dards  of  fatty  acids  for  a  concentration  of  0.1 
µg/ml.  Prior  to  use,  all  fibers  were  precondi-
tioned by  30 minutes  agitation in  a  methanol: 
water solution (1:1, v/v) in order to activate the 
silanol groups of the stationary phase. The ana-
lytes  spiked  in  plasma  were  pre-incubated  in 
room temperature for 60 min prior extraction to 
allow establishment ofprotein binding, knowing 
that the binding rate of fatty acid to albumin is 
rapid. 40 The SPME experiment was performed by 
immersing  the  fibers  into  1  mL  of  sample 
aliquots for 60 min extraction time with 800 rpm 
orbital shaking (model DVX-2500, VWR Interna-
tional,  Mississauga,  ON).  Immediately  after  ex-
traction, fibers were rinsed in purified water for 
10 s to remove any remains of biological material 
from the coating surface, followed by 60 minutes 
desorption  in  1  ml  acetonitrile  with  agitation 
(1000  rpm)  .  Extracts  were  further  injected  to 
HPLC–ESI-MS system for analysis. Percentage of 
extraction efficiency (or percent absolute recov-
ery) was calculated as the ratio of the amount 
extracted versus total amount of fatty acid spiked 
× 100%. Development of more detailed experi-
mental protocol can be found in the Supporting 
Information.
LC-ESI-MS  Operating  Conditions  All  samples 
were analyzed using an HPLC-ESI-MS system con-
sisting  of  two  Varian  212-LC  pumps  (Walnut 
Creek,  CA),  a  Prostar  430  autosampler,  and  a 
500-MS ion trap mass spectrometer (Varian, Palo 
Alto, CA). Data acquisition and processing were 
performed  using Varian MS  Workstation  soft-
ware (Version 6.6). Chromatographic separation 
was performed on an Ascentis® Express C18 RP-
LC column (2.1 x 150 mm , 2.7 μm). The binary 
gradient run consisted of  eluent A (90% water, 
10% Methanol) and B (80% methanol, 20% ace-
tonitrile) at room temperature with a flow rate of 
0.3 mL/min and 10 µl injection volume. Optimal 
separation was achieved using the following sol-
vent gradient elution: Mobile B starts with 60% 
holding for 1 min (min 0–1),  increasing to 95% 
(min 1–2), increasing to 100% (min 2–5), held for 
one minute (min 5–6), then ramped back to 60% 
over thirty seconds, followed by two more min-
utes  of  re-equilibration resulting in  a  total  run 
time of eight minutes. All fatty acids were ana-
lyzed at negative ionization mode (forming [M-
H]-) and were monitored in full scan mode. The 
optimum MS parameters were as follow: capil-
lary voltage: 90–110 V, RF loading of 80-90, ion 
spray voltage -4500 V and drying gas tempera-
ture 400 °C. The Figure S-1 in Supplementary In-
formation  shows  the  examples  of  XIC  chro-
matograms of fatty acids from human plasma ex-
tract.
Determination  of  Protein  Affinity  Constant 
(Ka) The extraction recovery of NEFAs was mea-
sured at different human serum albumin (HSA) 
concentrations to determine if variations in HSA 
level  affect  the  free  concentration  and  conse-
quently the extraction recovery of studied fatty 
acids.  Human  serum  albumin  (essentially  fatty 
acid and globulin free) was dissolved in PBS buf-
fer solution (pH 7.4) to reach protein concentra-
tions of 0, 5, 10, 20, 30, 40, 50, 60, 70 and 100 
g/L, These solutions were then spiked with fatty 
acids standards to reach the concentration of 3 
µg/mL in all solutions. The study was conducted 
in duplicate.
Determination of plasma protein binding: in-
vestigation of free and total concentrations  The 
determination  of  plasma  protein  binding  by 
SPME is based on the quantification of the free 
concentration  of  ligand  in  the  presence  of 
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plasma proteins.41–47 In order to have a better un-
derstanding of plasma protein binding, the cali-
bration curves were not only constructed in PBS 
and plasma, they were also constructed in stan-
dard human serum albumin solution (essentially 
fatty acid free) to mimic the plasma with only al-
bumin as binding agent. Linearity was verified by 
analyzing spiked plasma samples  at the concen-
trations  of 0, 1,  2,  3, 4, 5, and 7 µg/mL, with 
three replicates  in each point. After incubation 
allowing  for  protein  binding  equilibrium  (60 
min), extractions from PBS, serum albumin and 
plasma samples were performed under the same 
conditions  using  SPME  fibers.  Batch-to-batch 
precision  was  determined  according  to  Ma-
tuszewski et al.48 Five different sources of human 
plasma at all concentrations (n=3 for each point) 
were utilized for the construction of standard ad-
dition calibration curves. 
 RESULTS AND DISCUSSIONS
HPLC-ESI-MS  Electrospray  ionization  in  nega-
tive mode was chosen because fatty acids form 
[M−H]─ quasimolecular  ions  due  to  their  car-
boxylic acid moiety. Disregard of the applied col-
lision energy level, the product ion spectrum of 
[M−H]− in MRM mode was also dominated by the 
unfragmented deprotonated molecular ions of a 
low  sensitivity.  The  lack  of  production  of  de-
tectable  fragments  in  ESI-MS/MS  has  been  al-
ready  described  for  underivatized  FAs.49 Peak 
widths of 4–6 s were found and chromatographic 
resolution could be achieved in a total run time 
of  8  min.   Based  on  the  chromatographic 
method,  a  two-carbon  increase  in  fatty  acid 
chain length increases the retention time by ~1.8 
min, whereas introduction of a double bond, de-
creases retention time by ~0.7 min.
SPME method development  The experimental 
standard procedure was followed based on pre-
viously published SPME protocol for method vali-
dation.50 The properties of the C18 biocompati-
ble fibers was described in details elsewhere.51,52 
Extraction: The extraction time profile was ob-
tained in both PBS and plasma. The results re-
garding to extraction efficiency obtained in PBS 
solution as a matrix free media are described in 
Supporting Information (section 2.2). The initial 
stages of extraction time profile for all fatty acids 
under study were similar in both PBS and plasma 
meaning  that  the  equilibrium  was  achieved  in 
both media within first two hours. However, af-
ter  four  hours  of  extraction in  plasma,  the ex-
tracted amount started to increase reaching sec-
ond plateau after 10 hours and remaining con-
stant  for  up  to more than 18 hours  extraction 
(Figure  S-2,  Supporting  Information).  Checking 
the physical appearance of the fiber, a jelly-like 
attachment around the fiber was observed after 
4 hours extraction with vortex agitation. The ini-
tiation  of  protein  attachment  was  observed 
around the metal part of the rod fibre which is in 
contact with plasma during long time aggressive 
agitation. This effect could be explained as a re-
sult  of  protein  attachment  to  the  surface  of 
metal.  The  coating biocompatibility  was  tested 
several times and has been reported previously; 
51,52 hence it is anticipated that this effect is only 
visible  for  longer  contact  of  fibre  with  aggres-
sively  agitated  sample.   Therefore,  extraction 
time must be long enough to meet sensitivity re-
quirement, and short and gentle to avoid the ini-
tiation of  protein aggregation around the fiber. 
Therefore,  the use of  800 rpm orbital  shaking, 
which  is  a  less  aggressive  agitation  approach 
compared to vortex agitation,  prevent the pro-
tein aggregation occurrence. The required time 
to reach equilibrium extraction in plasma for all 
nine  compounds  was  less  than  120  minutes; 
therefore, 2 hours was chosen as the optimum 
extraction time for the entire study. The evalua-
tion of washing,  desorption and carry over are 
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discussed  in  Supporting  Information  (section 
2.1). 
Evaluation of matrix effect and ionization sup-
pression  Matrix effect can be considered as the 
Achilles heel of quantitative mass spectrometric 
analysis. Matrix effect occurs when matrix mole-
cules coelute with the analyte of interest thus al-
tering the  ionization  efficiency  of  the  electro-
spray interface.48 Therefore, it is essential to em-
ploy appropriate strategies to minimize  the ion-
ization suppression or  enhancement  phenome-
non associated with matrix  effect.  SPME,  how-
ever,  is  a  clean  extraction  method,  where  the 
biocompatibility of the polymer coating prevents 
extraction of  macromolecules and other matrix 
components.  Moreover,  non-exhaustive  extrac-
tion by SPME fiber applies not only to the ana-
lyte of interest, but also possible interfering com-
pounds, thus eliminating or significantly minimiz-
ing  competition  in  ionization  process.  In  this 
study, the matrix effect was assessed using two 
different approaches including i) absolute matrix 
effect evaluation using the post-extraction spiked 
method described by Matuszewski et al.53 and ii) 
the sample extract dilution method.54 Calculation 
of  absolute  matrix  effect  involved  relating  the 
peak  area  obtained  from  a  neat  solvent  spike 
with  a  known  concentration  (S2)  to  the  peak 
area of  the blank extract,  which is  spiked with 
the same concentration of analyte standard after 
extraction (S1)
                                           (Equation 1)
ME values larger than 120% and smaller than 
80%  represent  significant  ionization  enhance-
ment or suppression for a given analyte. For this 
study, matrix effect (ME) values are reported in 
Table 1. Utilizing the proposed SPME method, no 
absolute matrix effect was observed. Additional 
proof is provided by evaluation of matrix effect 
using the Sample Extract Dilution Method (Sup-
porting Information, Section 2.3). 
Determination of albumin affinity constant by 
SPME In plasma, fatty acids are soluble in con-
centrations up to about 1 μM. Owing their low 
solubility in plasma, FAs require a transporter to 
increase  their  concentration in vascular and in-
terstitial compartments.  Human serum albumin 
(HSA) is the transport vehicle for free fatty acids 
and the main FA-binding protein in extracellular 
fluids55 which  binds  with  approximately  0.1-
2 mol per mole protein, under normal physiolog-
ical condition.56 Further increase of NEFA concen-
tration increases the bound NEFA proportion, ac-
cordingly.40 Because SPME extraction occurs via 
free concentration, the study of plasma protein 
binding (PPB%) and the effect  of  albumin con-
centration  on  fatty  acid  recovery  by  SPME 
seemed crucial for this study. The recovery pro-
file of NEFAs was measured at different HSA con-
centrations.  Amount  of  FAs  extracted  from 
spiked standard human albumin solutions were 
plotted against  the protein  concentrations (Cp), 
and the Ka was determined by fitting equation 2 
through the data points.57
                                                 (Equation 2)
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Where, C0 is  the amount extracted at  a  protein 
concentration  of  0,  and fup is  the  unoccupied 
fraction of protein. In this experiment, fup is ap-
proximately equal to 1 because the total protein 
concentration (5-100 g/L) was much higher than 
the spiked fatty acid concentration (3 µg/L). Fig-
ure 1 shows the absolute recovery calculated for 
each individual protein concentration. The refer-
ence range for albumin concentrations in human 
blood plasma is 34 to 54 g/L. In the exaggerated 
range of HSA (<20 and >70 g/L), protein concen-
tration  affects  the  recovery  of  fatty  acids  by 
changing its free concentration equilibrating with 
the SPME coating. However, these extreme val-
ues are not expected in plasma samples except 
of hyper- or hypoalbuminemia and in this study 
they  are  only  considered  in  order  to  evaluate 
fiber performance. As the results show in Figure 
1, absolute recovery is constant within the physi-
ological range of HSA concentration (30-60 g/L). 
Accordingly, the mean calculated  Ka values from 
this experiment were in the range 9.2 × 104 to 
4.3×105 M-1 (Table 2).  Affinity constant (Ka) was 
reported to be dependent on the fatty acids car-
bon chain length; it increases with an increase in 
length  and  decrease  of  the  number  of  double 
bounds in studied fatty acids.40 The obtained re-
sults  for  the  affinity  constant  using  the  SPME 
method follow the same pattern and correspond 
very well with literature values,55,58 which proves 
the validity  of  the proposed SPME method for 
the study of free concentration and protein bind-
ing of nonesterified fatty acids in biological sys-
tems. 
Plasma protein binding (PPB %) Binding equi-
librium  studies  for  long-chain  fatty  acids  to 
serum albumin are complicated because of the 
low ligand solubility. The aim of this part of the 
study  was  to  investigate  binding  equilibria  of 
long-chain fatty acids in human blood plasma un-
der  varying  conditions  and to  compare the re-
sults with observations on the affinity constant 
to serum albumin, which were discussed in the 
previous section. Plasma protein binding deter-
mination  by  SPME  method  has  been  reported 
based  on  the  measurement  of  bioactive  un-
bound concentrations of the ligand, which is of-
ten  referred as  the free concentration in  pres-
ence of plasma protein.59  
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Figure  1 Albumin  concentration-dependent  NEFA  recovery;  y-
axis represents the extraction recovery percentage of fatty acids 
from solutions with different albumin concentrations after 2 hr 
of extraction.
Briefly,  the  percentage  of  binding  to 
plasma proteins (PPB) is calculated from the total 
and free concentrations of analyte:
                                       Equation 3
Where Ctotal is  the  total  concentration  of  ligand 
and Cfree is  the  free  concentration  of  ligand  in 
plasma. Considering that the total ligand concen-
tration is directly proportional to the slope of the 
matrix-free calibration curve in PBS, and the free 
concentration  is  directly  proportional  to  the 
slope of matrix  match calibration;59  Equation 3 
becomes:
             Equation 
4
In  order  to  better  understand  the  FA  binding 
mechanism, the matrix  match calibration curve 
was not only constructed in plasma, it was also 
constructed in HSA standard buffered solutions 
(35  g/L).  Using  the  standard  slopes  obtained 
from these experiments, Equation 4 was applied 
for  determination of  PPB values of  nine PUFAs 
under study in both media; results are presented 
in  Table  1.  The  present  observations  demon-
strate that there are no significant variations in 
PPB values determined by SPME method using 
different approaches, and it correlates well with 
average literature values.40,58,60
 Fatty  acids  quantification  in  plasma  samples 
One  of  the  most  important  elements  of  assay 
validation is the evaluation of the effect of matrix 
on the results  of  quantitative determination of 
metabolites in biological fluids.61 Therefore, due 
to the limited  availability  of  plasma samples  it 
was essential to compare the reproducibility of 
standard addition calibration in different plasma 
lots  under  the  same extraction and  chromato-
graphic  conditions.  The  precision  and  accuracy 
values obtained in a single plasma lot using  the 
proposed SPME method ranged from 5 to 10%, 
and 95 to  110%,  respectively.  Moreover,  when 
the same validation was attempted in five differ-
ent plasma lots, the precision values were per-
suasive (7-14%) under identical  conditions.  The 
inter-lot and intra-lot reproducibility is reported 
in Table 1. The very small variability of slopes of 
calibration  curves  obtained  from  five  different 
plasma sources is a direct indicator of assay re-
producibility  and  serves as  a  good quantitative 
indicator of the absence of a relative matrix ef-
fect in the proposed SPME method. For quantifi-
cation of the fatty acids under study, the mean 
calibration  curve,  obtained  from  five  different 
plasma lots,  was  employed  to  extrapolate  and 
quantify the unknown amount of PUFAs in hu-
man  plasma.  Due  to  the  limited  availability  of 
fish plasma, the standard addition method was 
performed  in  an  individual  lot  of  pooled  fish 
plasma (three replicates for each concentration 
point). Data are summarized in Table 2. 
Comparison of NEFA composition in fish and hu-
man plasma In  general,  the mean of  standard 
calibration line slopes determined in human con-
trol  plasma  and  fish  plasma are  similar  for  all 
fatty acids, which serves as an excellent measure 
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of  absence of  a  relative  matrix  effect  not  only 
within the same individual, but also between in-
dividuals. The observed differences of the Y-axis 
intercept of the calibration equations clearly in-
dicate that the initial level of fatty acids is consid-
erably  higher in fish.  Total  plasma NEFA in the 
study  of  White  Sucker  species  ranged  from 
0.76 to 11.13 µg/mL, whereas for control human 
plasma only arachidonic acid was detectable in 
the  quantification  range.  The  amounts  of  DHA 
and EPA were significantly higher in fish plasma 
with a p value of 0.002 and 0.007, respectively, 
though  the  concentration  level  of  arachidonic 
acid was not statistically different between these 
two subjects with a nearly non-significant p value 
(0.78). These results are consistent with the erst-
while work done on the White Sucker fish, which 
indicated higher DHA and EPA, and lower AA.62–64
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Table 2 Linear dynamic range of fatty acid concentration in hu-
man and fish plasma samples
Human plasma cali-
bration(n=5)1 
Lot-to-
lot CV 
(%)2
Fish plasma calibra-
tion 4
Human 
plasma 
conc.(µg)3
 Fish plasma 
conc.(µg)5 
DHA y = 0.0041x + 0.67 5% y = 0.0044x + 26.9 LOD 11.1 ±0.2
DPA y = 0.0037x + 10.5 4% y = 0.0039x + 16.6 ND 6.6 ± 0.1
ADR y = 0.0019x + 1.6 5% y = 0.0019x - 0.5 ND LOD
DTA y = 0.0018x + 3.3 3% y = 0.0022x + 4.3 ND 3.0 ± 0.1
EPA y = 0.0041x +4.7 3% y = 0.0041x + 13.1 LOD 9.0 ± 0.1
ARA y = 0.0036x + 1.7 3% y = 0.0027x + 1.04 2.9± 0.1 2.7 ± 0.1
ETA y = 0.0026x + 0.8 4% y = 0.0025x + 0.4 1.2± 0.1 1.1 ± 0.01
STD y = 0.0034x + 1.26 4% y = 0.0044x + 1.1 ND 0.76 ± 0.01
ALA y = 0.0012x +1.5 5% y = 0.0011x + 5.2 2.8± 0.2 1.6 ± 0.1
1Mean of calibration equation of five different human plasma lots, three replicates each.
2Lot-to-lot variation of slope of calibration equations from five different sources of plasma 
3Primary concentration of fatty acids in human plasma extraction, total µg
4Mean of calibration equation obtained from single human plasma lot, three replicates.
5Primary concentration of fatty acids in fish plasma extraction, total µg
Table 1 Evaluation of albumin affinity constant and % plasma protein binding 
DHA EPA ADR DTA EPA ARA ETA SDA ALA
Matrix Effect (%) 103% 96% 88% 91% 116% 110% 93% 112% 116%
Albumin affinity con-
stant (M-1) 9.2×10
4 2.1×105 2.2×105 4.3×105 1.2×105 1.5×105 2.9×105 2.0×105 2.2×105
Human serum albu-
min PPB (%) 97.9 98.6 99.1 99.4 98.0 98.6 99.2 99.5 99.6
Plasma PPB (%) 98.3 99.3 99.5 99.7 98.7 98.8 99.6 99.5 99.6
Intra-batch repro-
ducibility (%) 6 10 6 9 5 5 6 6 10
Inter-batch repro-
ducibility (%) 9 14 8 9 11 8 7 7 12
PPB values are found with (± 0-0.2) standard deviation and the correlation coefficient (CV) lower than 15%.
 Our results confirm the well known fact that fish 
is an omega-3 rich food choice because of its pri-
mary source of essential fatty acids and demon-
strate that presented analytical protocol can be 
used for  assessing the nutritional  value of  fish 
products in simple and relatively fast manner.
Clinical data analysis Using the validated SPME 
method,  fatty acid  changes  were monitored  in 
seven patients. As the results indicate in Figure 3, 
the  major  changes  in  concentration of  unsatu-
rated fatty acids during the surgery refer to the 
period when the patient is placed on CPB (Table 
2).  Pre-operative  or  intra-operative  metabolic 
changes  in  cardiac  surgical  patients  are  widely 
discussed in the literature.65–67 From a metabolic 
point of view, the cardiovascular response to in-
creased metabolic demands after cardiac surgery 
may lead to enhanced glucose and down regu-
lated  free fatty acid  (FFA)  metabolism;  yet  the 
heart  can use several  substrates,  among which 
free fatty acids (FFAs) and glucose are the major 
sources.65 Having known this fact, the reason be-
hind fatty acid elevation right after commencing 
bypass could be clearly explained. The alteration 
in metabolic profile of ALA and its  metabolites 
was already reported and discussed in the stud-
ied group of patients and current targeted analy-
sis confirms previous findings.38
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 CONCLUSION
This research aims to develop a simple unbiased 
analytical  method based on SPME in  combina-
tion  with  LC-MS  method  for  the  extraction  of 
free fatty acids  from human and fish plasma. It 
was  shown that  the  use of  biocompatible  C18 
SPME  fibers  could  be  successfully  applied  for 
quantification  and  qualitative  profiling  of  this 
group of lipids. This method permits the avoid-
ance of  interferences from hydrolysis  of  esteri-
fied  fatty  acids  from  other  lipid  sub-classes. 
Moreover,  the  protein  affinity  constant  of 
polyunsaturated fatty acids has been determined 
and compared to the literature values.  Indeed, 
the  obtained  results  indicate  the  selectivity  of 
the proposed method for  the determination of 
fatty acid species despite  their  slight  structural 
differences  in  carbon  chain  length  and  double 
bond number and localization. The extensive val-
idation of the method demonstrates the fulfill-
ment  of  requirements  for  the  bioanalytical  as-
says.  The  results  of  calibration  equations  ob-
tained from fish  and human plasma suggested 
that  this  approach  could  be  extended  to  the 
plasma samples of other biological species. The 
application of the protocol allowed for the suc-
cessful monitoring of the elevation of fatty acids 
in plasma collected from a group of patients un-
dergone cardiac surgery right after initiation of 
extracorporeal  circulation.  The  promising  out-
comes of the study show the potential of the ap-
proach  for  profiling  and  quantification  of  fatty 
acids in vivo in low invasive way as it was already 
demonstrated for other fiber-based SPME appli-
cations.28,31,68–71 The presented method could be 
also adopted for high throughput in vitro analysis 
either in its fiber form or using thin-film geome-
try format using automated 96-SPME device au-
tosampler.72
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